Skip to content
Screener

Cumberland Pharmaceuticals CPIX EPS (Diluted)

EPS (Diluted) at other companies

Baxter International logo
Baxter InternationalBAX
-$0.03-112%
PTH
Pelthos TherapeuticsPTHS
-$3.09+3.7%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$0.44-30.2%
RFL
Rafael Holdings, Inc.RFL
-$0.08+57.9%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$0.78+17.9%
Opko Health logo
Opko HealthOPK
-$0.01+94.7%

Other financials

Income statement

See full
Revenue$166.5K-56.3%
Gross profit$7.2M-30.0%
Operating income-$3.2M-1.3%
Net income-$4.3M-477%

Balance sheet

See full
Cash & equivalents$3.9M-76.0%
Total debt$4.7M-7.6%
Total equity$17.4M-37.7%
Total assets$62.9M-7.4%

Cash flow

See full
Operating cash flow$168.7K-80.0%
CapEx$38.3K+44.5%
Free cash flow$130.5K-84.0%

Valuation

See full
Market cap$134.4M+164%
Enterprise value$135.25M+239%
P/S4.3×+2.7×

Profitability

See full
Gross margin77.2%-7.1pp
Operating margin-30.8%+135pp
Net margin-34.9%-54.7pp
FCF margin2.2%—

Returns & leverage

See full
Return on equity-48.1%-67.6pp
Debt / equity0.3×+0.1×
Current ratio1×-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Cumberland Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 5:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001087294-26-000062
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
- Discontinued operations - basic(0.08)0.15(0.11)0.41
$(0.29)$(0.05)$(0.51)$0.03
- Continuing operations - diluted$(0.21)$(0.20)$(0.40)$(0.37)
- Discontinued operations - diluted(0.08)0.15(0.11)0.41
$(0.29)$(0.05)$(0.51)$0.03
Weighted-average shares outstanding
- basic14,981,60714,960,59614,970,96814,951,609
- diluted14,981,60714,960,59614,970,96814,951,609

Item 1. Financial Statements (Unaudited)

FAQ

What is Cumberland Pharmaceuticals's EPS (diluted)?
Cumberland Pharmaceuticals (CPIX) reported EPS (diluted) of -$0.29 in Q2 2026.
How has Cumberland Pharmaceuticals's EPS (diluted) changed year-over-year?
Cumberland Pharmaceuticals's EPS (diluted) decreased by 480.0% year-over-year, from -$0.05 to -$0.29.
What is the long-term trend for Cumberland Pharmaceuticals's EPS (diluted)?
Over 4 years (2021 to 2025), Cumberland Pharmaceuticals's EPS (diluted) has grown at a -5.7% compound annual growth rate (CAGR), from -$0.24 to -$0.19.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Cumberland Pharmaceuticals's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude